A Two-Hour Brain Tumour Diagnosis in the Operating Room

NHS surgeons in England can now get a genetic diagnosis of a brain tumour while the patient is still on the operating table. The test shortens the wait from up to eight weeks to two hours The Guardian. NHS England started using the tool on 25 September 2026.

The test was developed by the Brain Tumour Research Centre of Excellence at the University of Nottingham. It reads the genetic code, the DNA instructions, inside a small tumour sample and gives a result in hours. It runs on a shoebox-sized sequencing machine, a device that reads DNA, made by Oxford Nanopore.

NHS England will first pilot the test in five specialist centres before wider rollout. They are Nottingham University Hospitals NHS Trust, University Hospitals Birmingham NHS Foundation Trust, Great Ormond Street Hospital NHS Foundation Trust, King's College Hospital and Newcastle Hospitals NHS Foundation Trust. Next, Bristol, Oxford, Leeds and Manchester will follow.

Earlier research on this approach produced detailed tumour classifications in under two hours from surgery, with a 100% success rate in that study group Oncology Central. Researchers said the method could allow treatment to start sooner. For some patients, a rapid result could open early access to clinical trials, studies that test new treatments. NHS England officials have said the near-term aim is to cut average diagnosis time from weeks to days Sky News.

Looking at what this means for clinical practice, the shift is about place as well as pace. Diagnosis used to happen after surgery, in a different lab and at a later date. Now classification can happen during the operation itself. That means decisions about whether to remove more tissue, how to manage recovery, and where to refer the patient can draw on tumour biology at once, not weeks later. Trial windows are often narrow. A result on the day of surgery lets teams spot eligible patients right away and talk to families without delay.

In my view, the pilot will test how hospitals use the test as much as how well the science works. The five centres have high patient volumes, expert pathology labs, team-based care and established referral routes. Key questions are how operating-room results are checked and recorded, who is allowed to act on them, and what happens if the rapid result differs from the final lab review. There is also an equity question. Starting in specialist hubs speeds learning, but access will vary until Bristol, Oxford, Leeds and Manchester join and rollout widens. How to balance central expertise with bedside use will affect cost, training and quality checks.

The broader context here is a health system trying to close the gap between treatment and information. Putting genomics in the operating room changes the usual order of work. The pilot will show whether hours saved also lead to earlier treatment starts, more trial entries and better coordinated care.